Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study. 2022

Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
Department of Anesthesiology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.

Fiberoptic bronchoscopy is a complex procedure with the need for sufficient patient anesthesia/sedation while maintaining safety. This trial aimed to evaluate the efficacy, safety, and pharmacokinetics of HSK3486 during fiberoptic bronchoscopy. This multicenter, double-blind, randomized, non-inferiority, parallel-group phase 3 trial was conducted in patients who underwent fiberoptic bronchoscopy. Patients randomly received HSK3486 0.4 mg/kg (N = 134) or propofol 2.0 mg/kg (N = 133). The primary efficacy endpoint was the successful rate of fiberoptic bronchoscopy, and secondary efficacy endpoints included successful induction of anesthesia/sedation, duration, time to being fully alert, and time to patient discharge. Safety assessments and drug concentrations were also measured. A total of 267 patients completed fiberoptic bronchoscopy, with a success rate of 100% and a 95% confidence interval of - 2.8 to 2.8% for the difference between the groups, which met the predesigned criteria of > - 8%, confirming the non-inferiority of anesthesia/sedation produced by HSK3486 compared to propofol. Among the secondary efficacy endpoints, only time to full alertness (median 8.50 vs. 6.00 min, P = 0.012) and time to discharge (median 13.00 vs. 9.87 min, P = 0.002) were slightly longer in the HSK3486 group. The incidence of adverse events was significant lower in the HSK3486 group (52.6 vs. 76.5%, P < 0.001) mainly because of less pain on injection (4.4 vs. 39.4%, P < 0.001) compared to the propofol group. HSK3486 had a similar terminal elimination half-life as propofol. HSK3486 exhibited non-inferiority anesthesia/sedation compared to propofol in patients undergoing fiberoptic bronchoscopy, and had a good safety profile with a lower incidence of pain on injection. Clinicaltrials.gov, NCT04111159, registered on 1 October 2019.

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D001999 Bronchoscopy Endoscopic examination, therapy or surgery of the bronchi. Bronchoscopic Surgical Procedures,Surgical Procedures, Bronchoscopic,Bronchoscopic Surgery,Surgery, Bronchoscopic,Bronchoscopic Surgeries,Bronchoscopic Surgical Procedure,Bronchoscopies,Surgeries, Bronchoscopic,Surgical Procedure, Bronchoscopic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000758 Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
D015742 Propofol An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. Disoprofol,2,6-Bis(1-methylethyl)phenol,2,6-Diisopropylphenol,Aquafol,Diprivan,Disoprivan,Fresofol,ICI-35,868,ICI-35868,Ivofol,Propofol Abbott,Propofol Fresenius,Propofol MCT,Propofol Rovi,Propofol-Lipuro,Recofol,2,6 Diisopropylphenol,ICI 35,868,ICI 35868,ICI35,868,ICI35868

Related Publications

Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
April 2024, Anesthesiology,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
January 2010, American journal of therapeutics,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
January 2022, Frontiers in pharmacology,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
January 2009, Chest,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
September 2016, Experimental and therapeutic medicine,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
November 2014, Saudi journal of anaesthesia,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
February 2022, European review for medical and pharmacological sciences,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
January 2022, Frontiers in pharmacology,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
October 2016, Medicine,
Zhen Luo, and Hong Tu, and Xiang Zhang, and Xiao Wang, and Wen Ouyang, and Xinchuan Wei, and Xiaohua Zou, and Zhaoqiong Zhu, and Yalan Li, and Wangning Shangguan, and Hui Wu, and Yaping Wang, and Qulian Guo
December 2023, Nigerian journal of clinical practice,
Copied contents to your clipboard!